Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Singh

Showing results (391-400 of 505) with videos related to

Pageof 51
Sort By:
Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
American Journal of Respiratory and Critical Care Medicine|January 30, 2010
Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary diseaseBenjamin L Nicholas, Paul Skipp, Sheila Barton, et al.
British Journal of Clinical Pharmacology|November 8, 2019
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokineticsDavid L Hava, Lisa Tan, Patrick Johnson, et al.
Biomarker Insights|September 30, 2017
Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow LimitationPhilip E Silkoff, Dave Singh, J Mark FitzGerald, et al.
Respiratory Research|March 22, 2020
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitisMirco Govoni, Michele Bassi, Stefano Vezzoli, et al.
Respiratory Research|February 11, 2022
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trialDave Singh, Jim M Wild, Dinesh Saralaya, et al.
JCI Insight|September 7, 2018
Attached stratified mucus separates bacteria from the epithelial cells in COPD lungsJoan Antoni Fernández-Blanco, Dalia Fakih, Liisa Arike, et al.
ERJ Open Research|March 22, 2019
Research highlights from the 2018 European Respiratory Society International Congress: airway diseaseFlorence Schleich, Andras Bikov, Alexander G Mathioudakis, et al.
The European Respiratory Journal|April 18, 2020
The effect of exacerbation history on outcomes in the IMPACT trialDavid M G Halpin, Mark T Dransfield, MeiLan K Han, et al.
Pageof 51

Showing results (391-400 of 505) with videos related to

Sort By:
Pageof 51
Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
American Journal of Respiratory and Critical Care Medicine|January 30, 2010
Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary diseaseBenjamin L Nicholas, Paul Skipp, Sheila Barton, et al.
British Journal of Clinical Pharmacology|November 8, 2019
A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokineticsDavid L Hava, Lisa Tan, Patrick Johnson, et al.
Biomarker Insights|September 30, 2017
Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow LimitationPhilip E Silkoff, Dave Singh, J Mark FitzGerald, et al.
Respiratory Research|March 22, 2020
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitisMirco Govoni, Michele Bassi, Stefano Vezzoli, et al.
Respiratory Research|February 11, 2022
Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trialDave Singh, Jim M Wild, Dinesh Saralaya, et al.
JCI Insight|September 7, 2018
Attached stratified mucus separates bacteria from the epithelial cells in COPD lungsJoan Antoni Fernández-Blanco, Dalia Fakih, Liisa Arike, et al.
ERJ Open Research|March 22, 2019
Research highlights from the 2018 European Respiratory Society International Congress: airway diseaseFlorence Schleich, Andras Bikov, Alexander G Mathioudakis, et al.
The European Respiratory Journal|April 18, 2020
The effect of exacerbation history on outcomes in the IMPACT trialDavid M G Halpin, Mark T Dransfield, MeiLan K Han, et al.
Pageof 51